Company intelligence / Profile preview

Cyagen

Santa Clara, California, USAcyagen.com ↗

Ownership: Private
Employees: ~900
Development stage: Preclinical

Overview

Cyagen is not a therapeutics developer but provides advanced animal models, viral vectors, and AI-driven platforms to accelerate basic research and preclinical drug discovery. Their technologies have enabled the publication of over 10,925 academic articles in top journals such as Cell, Nature, and Science. They offer one-stop solutions for genetically modified rodent models and innovative cell/gene therapy R&D.

Therapeutic areas: ImmunologyMetabolic DisordersOncologyOther
Modalities: Gene therapyCell therapyViral vector (AAV) technologyMonoclonal antibodyCAR-T cell therapy
Industry: Drug Discovery Services

Partnerships

Extensive collaborations with scientists/institutions worldwide (>100 countries); no specific major pharma/biotech partnerships named publicly.

Beyond the preview

Go deeper on Cyagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyagen.

Explore the full profile